328 related articles for article (PubMed ID: 24436311)
1. New insights into the molecular pathogenesis of langerhans cell histiocytosis.
Rizzo FM; Cives M; Simone V; Silvestris F
Oncologist; 2014 Feb; 19(2):151-63. PubMed ID: 24436311
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of Langerhans cell histiocytosis.
Badalian-Very G; Vergilio JA; Fleming M; Rollins BJ
Annu Rev Pathol; 2013 Jan; 8():1-20. PubMed ID: 22906202
[TBL] [Abstract][Full Text] [Related]
3. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
[TBL] [Abstract][Full Text] [Related]
4. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
5. New insights into the pathogenesis of Langerhans cell histiocytosis.
de Graaf JH; Egeler RM
Curr Opin Pediatr; 1997 Feb; 9(1):46-50. PubMed ID: 9088755
[TBL] [Abstract][Full Text] [Related]
6. Apparent Lack of
Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
Front Immunol; 2019; 10():3045. PubMed ID: 31998317
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.
Murakami I; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Nagata K; Horie Y; Hayashi K; Imamura T; Morimoto A; Imashuku S; Gogusev J; Jaubert F; Takata K; Oka T; Yoshino T
Cell Commun Signal; 2015 Feb; 13():13. PubMed ID: 25889448
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the understanding of Langerhans cell histiocytosis.
Badalian-Very G; Vergilio JA; Degar BA; Rodriguez-Galindo C; Rollins BJ
Br J Haematol; 2012 Jan; 156(2):163-72. PubMed ID: 22017623
[TBL] [Abstract][Full Text] [Related]
9. CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis.
Lonardi S; Scutera S; Licini S; Lorenzi L; Cesinaro AM; Gatta LB; Castagnoli C; Bollero D; Sparti R; Tomaselli M; Medicina D; Calzetti F; Cassatella MA; Facchetti F; Musso T; Vermi W
Cancer Immunol Res; 2020 Jun; 8(6):829-841. PubMed ID: 32238382
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.
Morimoto A; Oh Y; Nakamura S; Shioda Y; Hayase T; Imamura T; Kudo K; Imashuku S;
Cytokine; 2017 Sep; 97():73-79. PubMed ID: 28582647
[TBL] [Abstract][Full Text] [Related]
11. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
12. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis.
Kansal R; Quintanilla-Martinez L; Datta V; Lopategui J; Garshfield G; Nathwani BN
Genes Chromosomes Cancer; 2013 Jan; 52(1):99-106. PubMed ID: 22996177
[TBL] [Abstract][Full Text] [Related]
13. Langerhans cell histiocytosis: Current concepts and treatments.
Abla O; Egeler RM; Weitzman S
Cancer Treat Rev; 2010 Jun; 36(4):354-9. PubMed ID: 20188480
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis.
Jouenne F; Benattia A; Tazi A
Curr Opin Oncol; 2021 Mar; 33(2):101-109. PubMed ID: 33315630
[TBL] [Abstract][Full Text] [Related]
15. Langerhans cell histiocytosis.
Ladisch S
Curr Opin Hematol; 1998 Jan; 5(1):54-8. PubMed ID: 9515204
[TBL] [Abstract][Full Text] [Related]
16. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.
Aricò M
Br J Haematol; 2016 Jun; 173(5):663-70. PubMed ID: 26913480
[TBL] [Abstract][Full Text] [Related]
17. Localized Acral Sclerosing Langerhans Cell Histiocytosis: A New Form of Presentation of Cutaneous Langerhans Cell Histiocytosis.
Garrido MC; Salido-Vallejo R; Revilla E; Salvatierra J; Rodriguez-Peralto JL
Am J Dermatopathol; 2020 May; 42(5):356-359. PubMed ID: 31725482
[TBL] [Abstract][Full Text] [Related]
18.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
19. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?
Berres ML; Merad M; Allen CE
Br J Haematol; 2015 Apr; 169(1):3-13. PubMed ID: 25430560
[TBL] [Abstract][Full Text] [Related]
20. Eruptive Junctional Nevi Appearing During Langerhans Cell Histiocytosis Treatment.
Mendonça-Sanches M; Rolim I; Costa-Rosa J; Caldas G; Moura C
Eur J Case Rep Intern Med; 2019; 6(6):001088. PubMed ID: 31293989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
